Trial Profile
A Phase I/II Study of Lintuzumab-Ac225 in Older Patients With Untreated Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Mar 2022
Price :
$35
*
At a glance
- Drugs Lintuzumab Ac-225 (Primary) ; Cytarabine; Furosemide; Spironolactone
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Actinium Pharmaceuticals
- 22 Feb 2022 Status changed from active, no longer recruiting to completed.
- 22 Feb 2022 Status changed from active, no longer recruiting to completed.
- 18 Nov 2020 Planned End Date changed from 1 Jun 2020 to 1 Mar 2021.